bluuebunny/crossref_metadata_2025_split huggingface dataset:
Perspectives on Refugeehood and Motherhood: Germany-Based Ukrainians’ Life Aspirations over Time
Authors: Rock Jonna 
Published: January 2025

Abstract
Drawing from the experiences of thirty-two refugee women who fled with their children from Ukraine to two German cities, Berlin and Frankfurt Oder, this article explores how being a refugee and a mother affects the anchoring, along with the un-anchoring and embedding of Ukrainian refugees in their new environment. It illustrates that solidarity practices and (inter)actions play a crucial role in mobility considerations, as the interlocutors engaging in solidarity work find meaning in building lives in their new environment. The identities of the interlocutors as refugees and mothers play an important role in shaping the solidarity they articulate as they work to support others in a similar situation in cultivating agency, which, at the same time, gives the interlocutors comfort in their own struggles. This article also makes a valuable contribution to the scholarly literature on transnational family ties through the case of Ukrainian refugee women in Germany, who often have family members remaining in/returning to Ukraine. The interlocutors positioning as mothers and refugees means that they engage in negotiating mobility considerations with these positions in hindsight — providing new avenues of enquiry into the agency of refugee-mothers, reflecting on life aspirations, and considering their specific positionalities and forced migration context.
The Mormon Archive’s First Ten Thousand Years: Infrastructure, Materiality, Ontology, and Resurrection in Religious Transhumanism
Authors: Bialecki Jon 
Published: January 2025

Abstract
One of the chief debates in the academic study of transhumanism is whether or not this emergent movement that advocates for the technological overcoming of the limits of humanity should be considered religious in nature. This question stems from the fact that, while the vast majority of transhumanists explicitly reject established religion, elements of transhumanism seem strikingly similar to Christian eschatology. This article explores this question by asking how the ontology of an avowedly religious transhumanist movement, the Mormon Transhumanist Association, differs from the informatic ontology identified in secular transhumanism. It shows how contemporary Mormon Transhumanist imaginings of various forms of technological resurrection are informed by the infrastructure and materialist ontology associated with the Mormon practice of “Proxy baptisms” (otherwise known as baptisms for the dead) and other initiatory rituals conducted by proxy on behalf of the deceased. This influence suggests that, at least in this case, there are identifiable differences between secular transhumanism and religious transhumanism that complicate any easy reading of secular transhumanism as being crypto-religion.
Delayed exponence in Murrinhpatha: Stratal OT, not position classes
Authors: Popp Marie-Luise 
Published: January 2025

Abstract
In this paper, I analyze an intricate morphological pattern in Murrinhpatha which involves reordering of the dual marker ngintha and an alternation in the form of its adjacent morpheme. I will argue that the pattern strongly suggests an analysis in Stratal Optimality Theory: first, phonological correlates of morphological structure provide evidence for cyclic domains within the word. Second, the phenomenon can be derived using independently motivated morphological constraints, thus supporting the idea that morphology is an independent module of grammar with different optimization mechanisms, but the same stratal split as phonology. The cyclic architecture of the word provides a straightforward explanation for the placement of the dual marker and the resulting allomorphy of the classifier stem without resorting to ad hoc mechanisms such as position classes. Furthermore, the cyclic structure neatly accounts for multiple exponence of [dual] through the daucal (dual/paucal) classifier stem and ngintha. My analysis suggests that this overexponence results from the blocking of ngintha in the first cycle and the selection of the featurally more specific daucal stem. However, ngintha is not strictly bounded to the first cycle, and its realization is delayed until the second cycle.
Is the timing of eating relevant for weight loss?
Authors: Flanagan Alan 
Published: January 2025

Abstract
The potential influence of the timing of eating on body weight regulation in humans has attracted substantial research interest. This review aims to critically evaluate the evidence on timed eating for weight loss, considering energetic and behavioural components of the timing of eating in humans. It has been hypothesised that timed eating interventions may alter energy balance in favour of weight loss by enhancing energy expenditure, specifically the thermic effect of food. This energetic effect has been suggested to explain greater weight loss which has been observed with certain timed eating interventions, despite comparable self-reported energy intakes to control diets. However, timed eating interventions have little impact on total daily energy expenditure, and the apparent effect of time of day on the thermic effect of food largely represents an artefact of measurement methods that fail to account for underlying circadian variation in RMR. Differences in weight loss observed in free-living interventions are more likely explainable by real differences in energy intake, notwithstanding similar self-reported energy intakes. In addition, the energetic focus tends to overlook the role of behavioural factors influencing the timing of eating, such as appetite regulation chronotype-environment interactions, which may influence energy intake under free-living conditions. Overall, there is scant evidence that timed eating interventions are superior to general energy restriction for weight loss in humans. However, the role of behavioural factors in influencing energy intake may be relevant for adherence to energy-restricted diets, and this aspect remains understudied in human intervention trials.
Persecution and the Art of Demonstration
Authors: Shaw Beau 
Published: January 2025

Rasoul Namazi's Leo Strauss and Islamic Political Thought contains patient and perceptive readings of four texts Strauss devoted to Islamic political philosophy. My comments are limited to just one of those readings, that of “Fârâbî's Plato,” and to a single issue within it—the question of the identity of the philosopher or of philosophy. Namazi rightly recognizes the centrality of this question in “Fârâbî's Plato.” As Strauss writes in explaining Alfarabi's view of Plato's philosophy, “the central question concerns . . . the precise meaning of the philosopher” (361), and Namazi claims that it is “one of the main themes or even the theme of ‘Fârâbî's Plato’” (148, emphasis original).
Outbreak of Pseudomonas aeruginosa perichondritis associated with ear piercings and a contaminated water system
Authors: Brown Claire E. , Ready Derren , Willis Caroline , Sims Ben , Young Nick , Sheridan Elizabeth , Osbourne Helen , Jones Louise , Landy Yvette , Long Naomi , Walkden Amy , Turton Jane F. , Staniforth Karren , Moore Ginny , Parks Simon , Barkoci Patricia , Bird Sarah 
Published: January 2025

Abstract
In September 2023, the UK Health Security Agency’s (UKHSA) South West Health Protection Team received notification of patients with Pseudomonas aeruginosa perichondritis. All five cases had attended the same cosmetic piercing studio and a multi-disciplinary outbreak control investigation was subsequently initiated. An additional five cases attending the same studio were found. Seven of the ten cases had isolates available for Variable Number Tandem Repeat (VNTR) typing at the UKHSA national reference laboratory. Clinical and environmental P. aeruginosa isolates from the patients, handwash sink, tap water and throughout the wall-mounted point-of-use water heater (including outlet water) were indistinguishable by VNTR typing (11,6,2,2,1,3,6,3,11). No additional cases were identified after control measures were implemented, which included replacing the sink and point-of-use heater.
The lack of specific recommendations to control for P. aeruginosa within Council-adopted ear-piercing byelaws or national guidance means that a cosmetic piercing artist could inadvertently overlook the risks from this bacterial pathogen despite every intention to comply with the law and follow industry best practice advice. Clinicians, Environmental Health Officers and public health professionals should remain alert for single cases of Pseudomonas perichondritis infections associated with piercings and have a low threshold for notification to local health protection teams.
Mosses (Bryophyta) of the north-western region of Marambio (Seymour) Island, Antarctica
Authors: Cottet Agustina Celeste , Messuti María Inés , Ansaldo Martín , Dopchiz Laura Patricia 
Published: January 2025

AbstractMarambio (Seymour) Island is located in the James Ross Archipelago east of the Antarctic Peninsula. Although several research groups have carried out studies on the biodiversity on the island for decades, surveys of bryophytes have not been developed. That is why there are currently only six species of mosses recorded in the northern part of the island. During the 2021–2022 summer Antarctic field trip, 15 mosses species were surveyed in Marambio Island. Of the total number of collected species, nine are reported for the first time for Marambio Island. For the remaining four species, their distributions are now expanded to Marambio Island.
Evaluating Viloxazine ER (Qelbree) Administered with Psychostimulants For Pediatric ADHD: Analysis of a Phase 4 Safety Trial
Authors: Childress Ann , Hayman Kimberley , Asubonteng Kobby , Yarullina Ilmiya , Earnest Jami , Rubin Jonathan 
Published: January 2025

IntroductionViloxazine extended-release (ER) is an FDA-approved, nonstimulant medication for pediatric (≥6 years) and adult ADHD. Apart from use as monotherapy, nonstimulants may be combined with stimulants when patients experience inadequate response or difficulties with medication tolerability. This phase IV, open-label trial (NCT04786990) evaluated the safety and tolerability of viloxazine ER administration with psychostimulants in children and adolescents with ADHD. Differences between morning and evening use of viloxazine ER were also assessed.MethodsChildren and adolescents (6 – 17 years) experiencing inadequate response (ADHDRS-5 ≥24 and CGI-S ≥3) to psychostimulant treatment (methylphenidate or amphetamine) were enrolled. Subjects maintained stable stimulant use throughout the trial. Following an up to 4-week screening period, subjects continuing to show inadequate response received flexibly dosed viloxazine ER (100-400 mg/day children; 200-600 mg/day adolescents) each morning during Weeks 1-4 and each evening during Weeks 5-8. Safety, tolerability, and efficacy were assessed relative to Baseline, and for change from baseline for morning vs. evening dosing.Results56 subjects received viloxazine ER with 85.7% of these completing the study. Adverse events were reported by 55.4% of subjects, most commonly headache (17.9%), decreased appetite (12.5%), and upper respiratory tract infection (10.7%); onset was more common during AM dosing trial weeks [50% of subjects reported AEs during Weeks 1-4 and 36% during Weeks 5-8]. AEs were largely mild (32.1%) or moderate (21.4%) and led to discontinuation for 2 (3.6%) subjects. Baseline mean (SD) Investigator Rated-ADHD-Rating Scale 5th ed. (IR-ADHD-RS-5) score was 37.2 (8.35), n=56. Significant improvement in IR-ADHD-RS-5 was seen by Week 1[ -6.9 (8.16), n=56; P<.0001)] and continued through Weeks 4 and 8 [-13.5 (9.70) p<.0001 and -18.2 (9.99) p<.0001, respectively]. Over 50% of subjects were rated much or very much improved on CGI-I at endpoint. Scores on the sleep disturbance Scale for Children (SDSC) scale also improved at both Weeks 4 and 8 [-8.8 (14.03) P<.0001 and -10.3(17.39) P=.0002, respectively], as did Parent-ratings of morning and evening ADHD symptoms and behavior, suggesting that morning and evening administration of viloxazine ER were both efficacious.ConclusionsViloxazine ER showed acceptable safety and tolerability when administered with stimulant medications in this Phase IV open-label trial. Administration of viloxazine ER in the evening instead of the morning did not appear to affect safety, nor the trajectory of drug response or sleep improvement.FundingSupernus Pharmaceuticals, Inc.
Psychosis of Epilepsy: A Review of Diagnosis and Management
Authors: Booker Brittany , Rangoonwala Saqib , Imtiaz Ayyub , Chamoun Karla , Duffy Samuel , Zaidi Muhammad 
Published: January 2025

IntroductionNeurology and psychiatry have been linked together for a long period of time. One overlap demonstrated in the literature is the correlation between epilepsy with mood and psychosis. There is a big group of psychoses called the psychosis of epilepsy (POE); however, there is not much evidence about the diagnosis and management. Differentiation between POEs is difficult and is compounded by a lack of evidence-based guidelines on appropriate management. Even if you arrive at the diagnosis, POE can be difficult to manage. Some antiepileptic drugs (AEDs) cause psychiatric side effects and some antipsychotics may be epileptogenic. In this poster, we will discuss ways to diagnose and treat POE, as well as how to optimize certain AEDs in patients with POE.MethodsArticles were chosen from multiple databases, such as MEDLINE, Google Scholar, and PsychInfo, to gather evidence about the diagnosis and management of POE. Specific keywords, such as Psychosis, Epilepsy, Antipsychotic, Antiepileptic, and Electroencephalogram (EEG) were used. Articles talking about recommendations regarding the use of AEDs and antipsychotics in POE were extracted from these databases.ResultsPOE includes preictal, ictal, postictal, and interictal psychosis. Preictal psychosis is very rare and tends to present with dissociation and déjà vu. This is correlated with temporal lobe epilepsy and resolves after the seizure. Ictal psychosis will correspond with epileptic activity on EEG and can manifest as aggression, delusions, or hallucinations. Antipsychotics are contraindicated in this POE. Postictal psychosis usually presents as a combination of mood symptoms and grandiose delusions seen with interictal sharp epileptiform discharges on EEG. Interictal psychosis can be subtyped into brief and chronic, with brief occurring during periods of increasing seizure frequency and chronic having no association with seizures. They both present similar to symptoms seen in classic schizophrenia and antipsychotics are often utilized.Clozapine and chlorpromazine were found to have the highest seizure prevalence from second- and first-generation antipsychotics respectively, and the lowest was found with risperidone. AEDs that are commonly used in psychiatry, such as oxcarbazepine, carbamazepine, valproic acid, and lamotrigine are discussed in detail regarding their optimal dosing strategy for patients presenting with POE.ConclusionsDiagnosis and management of the various types of POE can be challenging due to the lack of literature. We recommend using the antipsychotic, risperidone, as it has shown to have the lowest seizure prevalence among all antipsychotics. Both neurologists and psychiatrists should keep POE on their differential when dealing with seizure patients with psychosis. It is crucial for psychiatrists to understand how to optimize AEDs in the management of POE as these patients are often seen on the consult service.FundingNo Funding
Impact of a Virtual Patient Simulation on Clinical Decision Making for Pediatric Patients with ADHD
Authors: Guevara Natalie , Lubarda Jovana , Wright Clinton , Mattingly Gregory 
Published: January 2025

ObjectivesAttention-deficit/hyperactivity disorder (ADHD) is a common childhood disorder that can persist into adulthood in up to two-thirds of patients. ADHD is a heterogeneous disease, with a wide spectrum of symptoms and severity. Thus, ADHD presents diagnostic and treatment challenges for clinicians. This study utilized an online, virtual patient simulation (VPS)-based continuing medical education intervention to improve the ability of psychiatrists to diagnose, assess, and treat pediatric patients with ADHD.MethodsA cohort of US-practicing psychiatrists who participated in the simulation-based education was evaluated. The simulation consisted of 2 patient cases that allowed learners to order lab tests, make diagnoses, and prescribe treatments in a manner matching the scope and depth of actual practice. Tailored clinical guidance (CG), based on current evidence and expert recommendation, was provided following each decision, followed by the opportunity for the learner to modify their decisions. Decisions were collected post-CG and compared with each user’s baseline (pre-CG) decisions using a McNemar’s test to determine P values (5% significance level, P <0.05). Data were collected from February 2022 through May 2022.ResultsThe assessment sample consisted of psychiatrists (n=420 for case 1, n=358 for case 2) who made clinical decisions within the simulation and proceeded to the concluding debrief section. As a result of clinical guidance provided through simulation, significant improvements (P<0.001) were observed in several areas of clinical care:•Assessing symptoms of ADHD using evidence-based tools/scales (70% relative improvement case 1; 100% relative improvement case 2)•Diagnosing ADHD and comorbidities across ages (162% relative improvement case 1; 370% relative improvement case 2))•Ordering evidence-based treatments for ADHD based on individual patient presentation (71% relative improvement case 1; 53% relative improvement case 2)ConclusionVPS that immerses and engages specialists in an authentic, patient-based, practical learning environment can significantly improve evidence-based clinical decision making for the assessment and appropriate management of patients with ADHD to improve patient outcomes.FundingMedscape Education, Supernus
Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study
Authors: Meltzer-Brody Samantha , Shirikjian Lara , Cooke Jennifer , LaGuerre Kevin , Moseley Margaret K , Li Sigui , Kile Deidre , Forrestal Fiona , Ona Victor , Levin Seth , Kotecha Mona , Lasser Robert , Joseph Judith F 
Published: January 2025

BackgroundZuranolone is an investigational positive allosteric modulator of synaptic and extrasynaptic GABAA receptors and a neuroactive steroid in clinical development as a once-daily, oral, 14-day treatment course for adults with major depressive disorder or postpartum depression (PPD). The randomized, double-blind, placebo-controlled SKYLARK Study (NCT04442503) demonstrated that zuranolone 50 mg significantly improved depressive symptoms (as assessed by 17-item Hamilton Rating Scale for Depression total score) at Day 15 (primary endpoint; p<0.001) and was generally well tolerated in adults with PPD.MethodsIn the SKYLARK Study, patients were randomized 1:1 to receive zuranolone 50 mg or placebo for 14 days. Safety and tolerability were assessed by the incidence and severity of treatment-emergent adverse events (TEAEs), rates of dose reduction and treatment discontinuation, as well as weight gain and sexual dysfunction.ResultsThe SKYLARK Study assessed safety data from 98 patients treated with zuranolone 50 mg and 98 patients treated with placebo. TEAEs were reported in 66.3% of zuranolone-treated patients and 53.1% of placebo-treated patients. In patients that experienced TEAEs, most reported mild (zuranolone, 50.8%; placebo, 75%) or moderate (zuranolone, 44.6%; placebo, 23.1%) events. The most common (≥5%) TEAEs were somnolence (26.5%), dizziness (13.3%), sedation (11.2%), headache (9.2%), diarrhea (6.1%), nausea (5.1%), urinary tract infection (5.1%), and COVID-19 (5.1%) with zuranolone, and headache (13.3%), dizziness (10.2%), nausea (6.1%), and somnolence (5.1%) with placebo. Dose reduction due to TEAEs was 16.3% in patients receiving zuranolone vs 1.0% in patients receiving placebo; the most common TEAEs (>1 patient) leading to zuranolone dose reduction were somnolence (7.1%), dizziness (6.1%), and sedation (3.1%). Treatment discontinuation due to TEAEs was 4.1% in patients receiving zuranolone vs 2.0% in patients receiving placebo; TEAEs leading to zuranolone discontinuation in >1 patient included somnolence (2.0%). Serious TEAEs were reported in 2.0% of zuranolone-treated and 0% of placebo-treated patients; these included upper abdominal pain (1.0%, [1/98]), peripheral edema (1.0%, [1/98]), perinatal depression (1.0%, [1/98]), and hypertension (1.0%, [1/98]). Per investigators, serious TEAEs were not related to zuranolone. No signals for weight gain or sexual dysfunction were identified.ConclusionsIn adults with PPD, zuranolone 50 mg was generally well tolerated. Most TEAEs were mild or moderate in severity. Dose reduction due to TEAEs mainly resulted from somnolence, dizziness, and sedation, while treatment discontinuation due to TEAEs was low. No signals for weight gain or sexual dysfunction were identified.FundingSage Therapeutics, Inc., and Biogen Inc.
EMPOWERing the Next-Generation: A Phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia
Authors: Konis George , Koenig Erica , Takahashi Koji , Iredale Philip , Tugnait Meera , Waksman Javier , Chang Ih , Blackmon Shauna , Perry Pamela , Leoni Matt , Sanchez Raymond 
Published: January 2025

BackgroundEmraclidine is a novel, highly selective positive allosteric modulator of M4 muscarinic acetylcholine receptors currently in development for the treatment of schizophrenia and Alzheimer’s disease psychosis. By selectively activating M4 receptors, emraclidine may reduce excess dopamine signaling in the
striatum, potentially leading to a reduction in psychotic symptoms. Unlike current antipsychotics, emraclidine does not interfere with signaling at dopamine, serotonin, or histamine receptors, which can lead to adverse events. A previous phase 1b study supports further investigation of emraclidine. The phase 2 EMPOWER program will fully evaluate the efficacy, safety, tolerability, and dose-range of once-daily (QD) emraclidine in schizophrenia.MethodsEMPOWER-1 and EMPOWER-2 are two adequately powered, multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week inpatient studies of emraclidine monotherapy (10 mg QD, 15 mg QD, 30 mg QD). The trials are enrolling adult participants with schizophrenia who are experiencing an acute exacerbation of psychosis. Eligible participants will have a Positive and Negative Syndrome Scale (PANSS) Total Score between ≥85 and ≤120 and a Clinical Global Impression – Severity (CGI-S) score ≥4 at baseline. Both de novo participants and those who complete EMPOWER-1 or EMPOWER-2 will be eligible to participate in EMPOWER-3, a 52-week open label extension trial to evaluate the long-term safety and tolerability of emraclidine in adult participants with stable schizophrenia.ResultsDetailed study designs for the EMPOWER program will be presented. Primary outcome measure for EMPOWER 1 and 2 is change from baseline in PANSS total score at week 6. Other outcome measures include change from baseline in CGI-S score at week 6. Data from EMPOWER-3 will contribute to the overall evaluation of safety and tolerability of emraclidine in adult participants with schizophrenia.ConclusionsThe development of emraclidine is promising, as it selectively activates M4, a novel target that has been implicated in reducing psychotic symptoms while potentially avoiding many of the side effects currently associated with antipsychotics. The EMPOWER program aims to establish the efficacy, safety, tolerability, and appropriate dose-range of emraclidine in the treatment of schizophrenia.FundingCerevel Therapeutics